854 related articles for article (PubMed ID: 15106819)
1. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
[TBL] [Abstract][Full Text] [Related]
2. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
3. The treatment of osteoporosis. Antiresorptive therapy.
Miller PD
Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of bone quality. Bone quality and osteoporosis treatment].
Mashiba T
Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
Lufkin EG; Sarkar S; Kulkarni PM; Ciaccia AV; Siddhanti S; Stock J; Plouffe L
Curr Med Res Opin; 2004 Mar; 20(3):351-7. PubMed ID: 15025844
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
7. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
8. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Martens MG
J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
[TBL] [Abstract][Full Text] [Related]
9. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic therapy for the treatment and prevention of osteoporosis.
McClung B; McClung M
Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658
[TBL] [Abstract][Full Text] [Related]
11. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
Ohnaka K; Takayanagi R
Clin Calcium; 2009 Aug; 19(8):1118-24. PubMed ID: 19638695
[TBL] [Abstract][Full Text] [Related]
12. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis with antiresorptive drugs].
Vestergaard P; Mosekilde L; Brixen K
Ugeskr Laeger; 2005 Feb; 167(8):883-7. PubMed ID: 15789840
[No Abstract] [Full Text] [Related]
14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
15. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic strategies for osteoporosis].
Chapurlat R; Delmas PD
Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
[TBL] [Abstract][Full Text] [Related]
17. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
19. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of osteoporosis: current data and prospects].
Reginster JY; Deroisy R; Franchimont P
Rev Rhum Ed Fr; 1994 Dec; 61(10 Pt 2):155S-164S. PubMed ID: 7858567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
